Get started
Author

Peter A. Azorsa

Observed name: Peter Azorsa
ORCID: 0000-0003-3953-1151
Observed ORCID: 0000-0003-3953-1151
OpenAlex ID: A5033583281
Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma
2023 · Meijie Tian, Jun S. Wei, et al. · Cell Reports Medicine · 26
Abstract 5618: Anti-FGFR4 antibody drug conjugate for immune therapy of rhabdomyosarcoma and hepatocellular carcinoma
2018 · Adam Cheuk, Nitya Shivaprasad, et al. · Cancer Research · 9
Abstract A08: Development of FGFR4-specific chimeric antibody receptor (CAR) T cell and bispecific T cell engager (BiTE) for rhabdomyosarcoma (RMS) immunotherapy
2020 · Adam Cheuk, Nityashree Shivaprasad, et al. · Cancer Research · 3
Abstract 3338: A role for FGFR4 in growth and survival of Ewing sarcoma cells
2017 · Justin J. Montoya, Daniel H. Wai, et al. · Cancer Research · 2
Longitudinal Analysis of Matched Patient Biospecimens Reveals Neural Reprogramming of Cancer-Associated Fibroblasts following Chemotherapy in Pancreatic Cancer
2026 · Aylin Z. Henstridge, Peter A. Azorsa, et al. · Cancer Research · 1
Abstract B003: Developing an all-human model of perineural invasion in pancreatic cancer
2026 · Regina A. Casimiro-Núñez, Sydney Willey, et al. · Cancer Research
Abstract B078: Developing an all-human preclinical model of PDAC immunoreactivity
2026 · Peter A. Azorsa, Molly Goldwasser, et al. · Cancer Research
Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma
2024 · Meijie Tian, Jun S. Wei, et al. · Cell Reports Medicine
Abstract LB213: Potent antitumor activity of a FGFR4 CAR-T in rhabdomyosarcoma
2022 · Adam Tai Chi Cheuk, Meijie Tian, et al. · Cancer Research
Abstract 1885: Potent tumoricidal activity of a FGFR4 CART in rhabdomyosarcoma
2021 · Adam Cheuk, Meijie Tian, et al. · Cancer Research
Works count: 10
Citation count: 41
H-index: 3
I10-index: 1
Year
Topic
Type